

1 **Genes Required for the fitness of *Salmonella enterica* serovar Typhimurium**  
2 **During Infection of Immunodeficient *gp91<sup>-/-</sup>phox* Mice**

3

4 **Running title:** *Salmonella* TraDIS in immunodeficient mice

5

6 Andrew J. Grant<sup>1#</sup>, Olusegun Oshota<sup>1</sup>, Roy R. Chaudhuri<sup>1a</sup>, Matthew Mayho<sup>2</sup>, Sarah  
7 E. Peters<sup>1</sup>, Simon Clare<sup>2</sup>, Duncan J. Maskell<sup>1</sup>, Pietro Mastroeni<sup>1</sup>

8

9 **1** Department of Veterinary Medicine, University of Cambridge, Madingley Road,  
10 Cambridge, UK.

11

12 **2** Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,  
13 Cambridge, UK.

14

15 **a** Current address: Department of Molecular Biology and Biotechnology, University  
16 of Sheffield, Firth Court, Western Bank, Sheffield, UK.

17

18 # To whom correspondence should be addressed: [ajg60@cam.ac.uk](mailto:ajg60@cam.ac.uk)

19 **SUPPLEMENTAL INFORMATION**

20 **MATERIALS AND METHODS**

21 **Details of *S. Typhimurium* defined mutant generation.**

22 **Generation of SL1344 *aroC* mutant.** PCR was used to amplify the  
23 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
24 homology arms complementary to the flanking regions of *aroC* using the primers  
25 *ajg806* and *ajg807* (Table S2). The resulting product was further amplified using the  
26 primers *ajg805* and *ajg808* (Table S2) to generate sufficient product for  
27 chromosomal integration into SL1344. The correct genomic rearrangement in the  
28 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
29 primers *ajg804* and *ajg809* (Table S2).

30

31 **Generation of S12023 *aroC/aroD* mutant.** PCR was used to amplify the  
32 kanamycin resistance cassette from pACYC177 (S1) with 5' and 3' 60 bp homology  
33 arms complementary to the flanking regions of *aroD* using the primers *ajg812* and  
34 *ajg813* (Table S2). The resulting product was further amplified using the primers  
35 *ajg811* and *ajg814* (Table S2) to generate sufficient product for chromosomal  
36 integration into SL1344 *aroC*. The correct genomic rearrangement in the resultant  
37 mutant was confirmed by PCR and sequencing (data not shown) using the primers  
38 *ajg810* and *ajg815* (Table S2).

39

40 **Generation of S12023 *aroC/aroD/htrA* mutant.** PCR was used to amplify  
41 the kanamycin resistance cassette from pACYC177 (S1) with 5' and 3' 60 bp

42 homology arms complementary to the flanking regions of *aroD* using the primers  
43 *ajg812* and *ajg813* (Table S2). The resulting product was further amplified using the  
44 primers *ajg811* and *ajg814* (Table S2) to generate sufficient product for  
45 chromosomal integration into SL1344 *aroC*. The correct genomic rearrangement in  
46 the resultant mutant was confirmed by PCR and sequencing (data not shown) using  
47 the primers *ajg810* and *ajg815* (Table S2). Subsequently, PCR was used to amplify  
48 the tetracycline resistance cassette from pBR322 (S2) with 5' and 3' 60 bp homology  
49 arms complementary to the flanking regions of *htrA* using the primers *ajg818* and  
50 *ajg819* (Table S2). The resulting product was further amplified using the primers  
51 *ajg817* and *ajg820* (Table S2) to generate sufficient product for chromosomal  
52 integration into SL1344 *aroC/aroD*. The correct genomic rearrangement in the  
53 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
54 primers *ajg816* and *ajg821* (Table S2).

55

56 **Generation of SL1344 *aroC/ssaV* mutant.** PCR was used to amplify the  
57 kanamycin resistance cassette from pACYC177 (S1) with 5' and 3' 60 bp homology  
58 arms complementary to the flanking regions of *ssaV* and including the first 16  
59 nucleotides and last 11 nucleotides of *ssaV*, using the primers *ajg824* and *ajg825*  
60 (Table S2). The resulting product was further amplified using the primers *ajg823* and  
61 *ajg826* (Table S2) to generate sufficient product for chromosomal integration into  
62 SL1344 *aroC*. The correct genomic rearrangement in the resultant mutant was  
63 confirmed by PCR and sequencing (data not shown) using the primers *ajg822* and  
64 *ajg827* (Table S2).

65

66           **Generation of SL1344 *cydC* mutant.** PCR was used to amplify the  
67 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
68 homology arms complementary to the flanking regions of *cydC* using the primers  
69 *ajg836* and *ajg837* (Table S2). The resulting product was further amplified using the  
70 primers *ajg835* and *ajg838* (Table S2) to generate sufficient product for  
71 chromosomal integration into SL1344. The correct genomic rearrangement in the  
72 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
73 primers *ajg834* and *ajg839* (Table S2).

74

75           **Generation of SL1344 *cydC/cydD* mutant.** PCR was used to amplify the  
76 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
77 homology arms complementary to the flanking regions of *cydC cydD* using the  
78 primers *ajg842* and *ajg843* (Table S2). The resulting product was further amplified  
79 using the primers *ajg841* and *ajg844* (Table S2) to generate sufficient product for  
80 chromosomal integration into SL1344. The correct genomic rearrangement in the  
81 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
82 primers *ajg840* and *ajg845* (Table S2).

83

84           **Generation of SL1344 *cydD* mutant.** PCR was used to amplify the  
85 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
86 homology arms complementary to the flanking regions of *cydD* using the primers  
87 *ajg848* and *ajg849* (Table S2). The resulting product was further amplified using the  
88 primers *ajg847* and *ajg850* (Table S2) to generate sufficient product for  
89 chromosomal integration into SL1344. The correct genomic rearrangement in the

90 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
91 primers ajg846 and ajg851 (Table S2).

92

93       **Generation of SL1344 *cysE* mutant.** PCR was used to amplify the  
94 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
95 homology arms complementary to the flanking regions of *cysE* using the primers  
96 ajg854 and ajg855 (Table S2). The resulting product was further amplified using the  
97 primers ajg853 and ajg856 (Table S2) to generate sufficient product for  
98 chromosomal integration into SL1344. The correct genomic rearrangement in the  
99 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
100 primers ajg852 and ajg857 (Table S2).

101

102       **Generation of SL1344 *dksA* mutant.** PCR was used to amplify the  
103 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
104 homology arms complementary to the flanking regions of *dksA* using the primers  
105 ajg860 and ajg861 (Table S2). The resulting product was further amplified using the  
106 primers ajg859 and ajg862 (Table S2) to generate sufficient product for  
107 chromosomal integration into SL1344. The correct genomic rearrangement in the  
108 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
109 primers ajg858 and ajg863 (Table S2).

110

111       **Generation of SL1344 *ftsK* mutant.** PCR was used to amplify the  
112 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp

113 homology arms complementary to the flanking regions of *ftsK* using the primers  
114 *ajg866* and *ajg867* (Table S2). The resulting product was further amplified using the  
115 primers *ajg865* and *ajg868* (Table S2) to generate sufficient product for  
116 chromosomal integration into SL1344. The correct genomic rearrangement in the  
117 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
118 primers *ajg864* and *ajg869* (Table S2).

119

120 **Generation of SL1344 *miaA* mutant.** PCR was used to amplify the  
121 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
122 homology arms complementary to the flanking regions of *miaA* and including the first  
123 8 nucleotides of *miaA* using the primers *ajg896* and *ajg897* (Table S2). The resulting  
124 product was further amplified using the primers *ajg895* and *ajg898* (Table S2) to  
125 generate sufficient product for chromosomal integration into SL1344. The correct  
126 genomic rearrangement in the resultant mutant was confirmed by PCR and  
127 sequencing (data not shown) using the primers *ajg894* and *ajg899* (Table S2).

128

129 **Generation of SL1344 *nuo* operon mutant.** PCR was used to amplify the  
130 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
131 homology arms complementary to the flanking regions of the *nuo* operon using the  
132 primers *ajg902* and *ajg903* (Table S2). The resulting product was further amplified  
133 using the primers *ajg901* and *ajg904* (Table S2) to generate sufficient product for  
134 chromosomal integration into SL1344. The correct genomic rearrangement in the  
135 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
136 primers *ajg900* and *ajg905* (Table S2).

137

138           **Generation of SL1344 *nuoK* mutant.** PCR was used to amplify the  
139 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
140 homology arms complementary to the flanking regions of the *nuo* operon using the  
141 primers ajg908 and ajg909 (Table S2). The resulting product was further amplified  
142 using the primers ajg907 and ajg910 (Table S2) to generate sufficient product for  
143 chromosomal integration into SL1344. The correct genomic rearrangement in the  
144 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
145 primers ajg906 and ajg911 (Table S2).

146

147           **Generation of SL1344 *ptsI* mutant.** PCR was used to amplify the  
148 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
149 homology arms complementary to the flanking regions of *ptsI* using the primers  
150 ajg932 and ajg933 (Table S2). The resulting product was further amplified using the  
151 primers ajg931 and ajg934 (Table S2) to generate sufficient product for  
152 chromosomal integration into SL1344. The correct genomic rearrangement in the  
153 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
154 primers ajg930 and ajg935 (Table S2).

155

156           **Generation of SL1344 *recD* mutant.** PCR was used to amplify the  
157 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
158 homology arms complementary to the flanking regions of *recD* and including the first  
159 4 nucleotides of *recD* using the primers ajg950 and ajg51 (Table S2). The resulting

160 product was further amplified using the primers ajg949 and ajg952 (Table S2) to  
161 generate sufficient product for chromosomal integration into SL1344. The correct  
162 genomic rearrangement in the resultant mutant was confirmed by PCR and  
163 sequencing (data not shown) using the primers ajg948 and ajg953 (Table S2).

164

165 **Generation of SL1344 *secG* mutant.** PCR was used to amplify the  
166 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
167 homology arms complementary to the flanking regions of *secG* using the primers  
168 ajg992 and ajg993 (Table S2). The resulting product was further amplified using the  
169 primers ajg991 and ajg994 (Table S2) to generate sufficient product for  
170 chromosomal integration into SL1344. The correct genomic rearrangement in the  
171 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
172 primers ajg990 and ajg995 (Table S2).

173

174 **Generation of SL1344 *seqA* mutant.** PCR was used to amplify the  
175 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
176 homology arms complementary to the flanking regions of *seqA* using the primers  
177 ajg998 and ajg999 (Table S2). The resulting product was further amplified using the  
178 primers ajg997 and ajg1000 (Table S2) to generate sufficient product for  
179 chromosomal integration into SL1344. The correct genomic rearrangement in the  
180 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
181 primers ajg996 and ajg1001 (Table S2).

182



183           **Generation of SL1344 *sucA* mutant.** PCR was used to amplify the  
184 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
185 homology arms complementary to the flanking regions of *sucA* using the primers  
186 ajg1076 and ajg1077 (Table S2). The resulting product was further amplified using  
187 the primers ajg1075 and ajg1078 (Table S2) to generate sufficient product for  
188 chromosomal integration into SL1344. The correct genomic rearrangement in the  
189 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
190 primers ajg1074 and ajg1079 (Table S2).

191

192           **Generation of SL1344 *suc* operon mutant.** PCR was used to amplify the  
193 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
194 homology arms complementary to the flanking regions of the *suc* operon using the  
195 primers ajg1082 and ajg1083 (Table S2). The resulting product was further  
196 amplified using the primers ajg1081 and ajg1084 (Table S2) to generate sufficient  
197 product for chromosomal integration into SL1344. The correct genomic  
198 rearrangement in the resultant mutant was confirmed by PCR and sequencing (data  
199 not shown) using the primers ajg1080 and ajg1085 (Table S2).

200

201           **Generation of SL1344 *thdF* mutant.** PCR was used to amplify the  
202 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
203 homology arms complementary to the flanking regions of *thdF* using the primers  
204 ajg1052 and ajg1053 (Table S2). The resulting product was further amplified using  
205 the primers ajg1051 and ajg1054 (Table S2) to generate sufficient product for  
206 chromosomal integration into SL1344. The correct genomic rearrangement in the

207 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
208 primers ajg1050 and ajg1055 (Table S2).

209

210 **Generation of SL1344 *tol* operon mutant.** PCR was used to amplify the  
211 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
212 homology arms complementary to the flanking regions of the *tol* operon and  
213 including the last 4 nucleotides of *tolQ* using the primers ajg1058 and ajg1059 (Table  
214 S2). The resulting product was further amplified using the primers ajg1057 and  
215 ajg1060 (Table S2) to generate sufficient product for chromosomal integration into  
216 SL1344. The correct genomic rearrangement in the resultant mutant was confirmed  
217 by PCR and sequencing (data not shown) using the primers ajg1056 and ajg1061  
218 (Table S2).

219

220 **Generation of SL1344 *tol/pal* operon mutant.** PCR was used to amplify the  
221 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
222 homology arms complementary to the flanking regions of the *tol pal* operon and  
223 including the last 4 nucleotides of *tolQ* using the primers ajg1064 and ajg1065 (Table  
224 S2). The resulting product was further amplified using the primers ajg1063 and  
225 ajg1066 (Table S2) to generate sufficient product for chromosomal integration into  
226 SL1344. The correct genomic rearrangement in the resultant mutant was confirmed  
227 by PCR and sequencing (data not shown) using the primers ajg1062 and ajg1067  
228 (Table S2).

229

230           **Generation of SL1344 *yqiC* mutant.** PCR was used to amplify the  
231 chloramphenicol resistance cassette from pACYC184 (S1) with 5' and 3' 60 bp  
232 homology arms complementary to the flanking regions of *yqiC* using the primers  
233 *ajg1070* and *ajg1071* (Table S2). The resulting product was further amplified using  
234 the primers *ajg1069* and *ajg1072* (Table S2) to generate sufficient product for  
235 chromosomal integration into SL1344. The correct genomic rearrangement in the  
236 resultant mutant was confirmed by PCR and sequencing (data not shown) using the  
237 primers *ajg1068* and *ajg1073* (Table S2).

238

239 **SUPPLEMENTAL REFERENCES**

240

241 S2 **Chang, C.Y. and Cohen, S.N.** 1978. Construction and characterization of  
242 amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic  
243 miniplasmid. *J. Bacteriol.* **134**: 1141-1156.

244

245 S2 **Bolivar, F. Rodriguez, R.L. Greene, P.J. Betlach, M.C. Heyneker, H.L. and**  
246 **Boyer, H.W.** 1977. Construction and characterization of new cloning vehicles.  
247 II. A multipurpose cloning system. *Gene.* **2**: 95-113.

248

249 S3 **Chaudhuri, R.R. Morgan, E. Peters, S.E. Pleasance, S.J. Hudson, D.L.**  
250 **Davies, H.M. Wang, J. van Diemen, P.M. Buckley, A.M. Bowen, A.J.**  
251 **Pullinger, G.D. Turner, D.J. Langridge, G.C. Turner, A.K. Parkhill, J.**  
252 **Charles, I.G. Maskell, D.J. and Stevens, M.P.** 2013. Comprehensive  
253 assignment of roles for *Salmonella typhimurium* genes in intestinal  
254 colonization of food-producing animals. *PLoS. Genet.* **9**(4): e1003456.

255 **FIGURES AND TABLE LEGENDS**

256

257 **Figure S1.** (A) Histogram of fitness scores obtained during infection of C57/BL6  
258 mice. (B) Fitness scores obtained for mutants during infection of C57/BL6 mice  
259 compared with those obtained during infection of BALB/c mice (S3). (C) Comparison  
260 of raw number of reads obtained for each mutant from the livers of two replicate  
261 C57/BL6 mice.

262

263 **Figure S2.** (A) Histogram of fitness scores obtained during infection of *gp91<sup>-/-</sup>phox*  
264 mice. (B) Fitness scores obtained for mutants during infection of *gp91<sup>-/-</sup>phox* mice  
265 compared with those obtained during infection of BALB/c mice (S3). (C) Comparison  
266 of raw number of reads obtained for each mutant from the livers of two replicate  
267 *gp91<sup>-/-</sup>phox* mice mice.

268


269 **Table S1.** Primer sequences used in this study.

270

271 **Table S2.** Raw read counts, fitness scores and adjusted P values for 9,356  
272 transposon mutants during infection of *gp91<sup>-/-</sup>phox*, C57/BL6 and BALB/c mice.

273


274 **Table S3.** Raw read counts, fitness scores and adjusted P values for 447 transposon  
275 mutants significantly attenuated during infection of *gp91<sup>-/-</sup>phox* mice.



277

278 **Figure S1.** (A) Histogram of fitness scores obtained during infection of C57/BL6  
279 mice. (B) Fitness scores obtained for mutants during infection of C57/BL6 mice

280 compared with those obtained during infection of BALB/c mice (S3). (C) Comparison  
281 of raw number of reads obtained for each mutant from the livers of two replicate  
282 C57/BL6 mice.



284

285 **Figure S2.** (A) Histogram of fitness scores obtained during infection of  $gp91^{-/-}phox$

286 mice. (B) Fitness scores obtained for mutants during infection of  $gp91^{-/-}phox$  mice



287 compared with those obtained during infection of BALB/c mice (S3). (C) Comparison  
288 of raw number of reads obtained for each mutant from the livers of two replicate  
289 *gp91<sup>-/-</sup>phox* mice mice.

Primer	Sequence 5' to 3'
SplA5_top	gagatcgggtctcggcatttctgctgaaccgctcttccgatct
SplA5_bottom	/5phos/gatcgggaagagcgggttcagcagggtttttttttcaaaaaaa
Mu_AG_5' PCR	aatgatacggcgaccaccgagatctacaccgaattcattaccctggtatccctatttaggtgac
Mu_AG_3' PCR	aatgatacggcgaccaccgagatctacaccggaatcctctagagtcgactggcaaac
Tn5_AG_5' PCR	aatgatacggcgaccaccgagatctacaccctaccctgtggaacacctacatctgtattaacg
Tn5_AG_3' PCR	aatgatacggcgaccaccgagatctacaccggaatcctctagagtcgactggcaaac
Mu_AG_5' seq	gtgaaacgcttttcgctttttctgtgcg
Mu_AG_3' seq	gtgaaacgcttttcgctttttctgtgcg
Tn5_AG_5' seq	ccctgttatccctatttaggtgacactatagaagagatgtgta
Tn5_AG_3' seq	atgggtattatgggtaatacgaactcactatagggagatgtgta
SplAP5.1	caagcagaagacggcatacagagataacgtgatgagatcgggtctcggcattcc
SplAP5.2	caagcagaagacggcatacagagataaaacatcggagatcgggtctcggcattcc
ajg804	cggttcacctggctggagttt
ajg805	acatttcaatatttataaaga
ajg806	acatttcaatatttataaagattaaaaacgcaaacgacaacacgataacggagccgtgacgacactttgcccgaat
ajg807	cgccaggctggcgctactgacaaacctgccagcagcgaatcgcggtttttttcatttcttacgccccgacctgacct
ajg808	cgccaggctggcgctactgac
ajg809	atgatgcatccgttggcaaaag
ajg810	atggtgttatggcaaggagcc
ajg811	gggattcacagcctgaccggt
ajg812	gggattcacagcctgaccggtaaaattataatgacgacaatgacaatgaaggttaccaactcaaaatctctgatgttac
ajg813	gtcagataaactattttattttatgtggtgagaaagagaatattccgccacacgataaaagtattagaaaaactcatcgagca
ajg814	gtcagataaactattttattttta
ajg815	ttatccctgaaaacaatatcg
ajg816	tcgaacagtaaatggactttt
ajg817	ataaaatgaatctgacgtaca
ajg818	ataaaatgaatctgacgtacacagcaattttgcgttacctgttaatcgagattgaaacacttgacagcttatcatcgata
ajg819	tgtggggggtttcacagaaaagtgttgccttccatggcgggaaggggggacaaaggtgatcaggtcgaggtggccccggc
ajg820	tgtggggggtttcacagaaaa
ajg821	tgagcagagcacaagcataag
ajg822	gtattcctcaacgattatttt
ajg823	tggttacgattacatcatcga
ajg824	tggttacgattacatcatcgacaaaataaaatttctggagtcgcaatgcgttcatggttagctcaaaatctctgatgttac
ajg825	acaataaccatcggggggggataatttcagcctcagacgttgcatcaattcatttcttatttagaaaaactcatcgagca
ajg826	acaataaccatcgggggggcg
ajg827	cagcacaactcgccataaat
ajg834	agttggaagatctcgccgact
ajg835	ctcagcgcggccaacgcgct
ajg836	ctcagcgcggccaacgcgcttttgcgacgttatttgctcaccgtcagggatatttaacgacgactttgcccgaat
ajg837	gctgaaccagacgcatgacggcgaaactccagtagcgaagtcggatcgttcaataatagcttacgccccgacctgacct
ajg838	gctgaaccagacgcatgacgg
ajg839	gctgaaccagacgcatgacgg
ajg840	gatggtctggccgacgcgagc
ajg841	tttgcgtcgttgtaacattgc
ajg842	tttgcgtcgttgtaacattgcctgctgaaattccaataactcacctgctaagcgtgcacgacgactttgcccgaat
ajg843	gctgaaccagacgcatgacggcgaaactccagtagcgaagtcggatcgttcaataatagcttacgccccgacctgacct
ajg844	gctgaaccagacgcatgacgg
ajg845	atcgccgcccagcgcagtaa
ajg846	gatggtctggccgacgcgagc
ajg847	tttgcgtcgttgtaacattgc
ajg848	tttgcgtcgttgtaacattgcctgctgaaattccaataactcacctgctaagcgtgcacgacgactttgcccgaat
ajg849	cagcgttagcatccatttatggcgtttataaagcgtcagataagggagtagcgcgacatttacgccccgacctgacct
ajg850	cagcgttagcatccatttatg
ajg851	gcggacgaggacaggaaccag
ajg852	gcgcgcgaggcagcattaacg
ajg853	cataaacgaccaaccgcac
ajg854	cataaacgaccaaccgcacagaaacgggttgctgcttttctgcccgtctggagtaagcccagcactttgcccgaat

ajg855	gctccgctgttccgggattgcaactccatcggaacagcgttttttagttgtaccgcaatattaacgccccgcctgccact
ajg856	gctccgctgttccgggattgc
ajg857	atatctgtttatcgtcggccc
ajg858	gtgcgtaaacacgcttttcct
ajg859	atagcgacctgattttccccc
ajg860	atagcgacctgattttccccgaacatggggatcgatagtgctgttaaggagaagcaaccgacgcactttgcccgaat
ajg861	caataaagaataaggcgggaaaactcccgcctgtcataaatagggtagaaacgaacgggattacgccccgcctgccact
ajg862	caataaagaataaggcgggaa
ajg863	gattaacgagccgaaatgcag
ajg864	cgctaacacggaacaggtgca
ajg865	ccggtgctgttgcctttta
ajg866	ccggtgctgttgccttttagcatcggcgggaaaagcctggaacctggagagccttttcgacgcactttgcccgaat
ajg867	agaaaatactgaattttgttgcggatggcagcctgcacagcggcctacagggttacgccccgcctgccact
ajg868	agaaaatactgaattttgttgc
ajg869	ttattcctcaggtttcgacac
ajg894	cgcagtggtcgatggcgagg
ajg895	ggtggcctgttacaacctggt
ajg896	ggtggcctgttacaacctggtgatttacattcggcgatgaacgcctgaagcatgaatgacgacgcactttgcccgaat
ajg897	ttgtactttgaaaccttcgattctgaaaaattgcgcacgatacgtctcaattgtacacatttaacgccccgcctgccact
ajg898	ttgtactttgaaaccttcgat
ajg899	cacgttcccgcgcaatgcgt
ajg900	gtaaaaaacacatcaattag
ajg901	atgtggcgccccatctgcccga
ajg902	atgtggcgccccatctgcccgaatgagcagagaaaactggcgctacttttgatgagtaagcagcgcactttgcccgaat
ajg903	tattgctcatcagcctcaaccgcccataaatcggcggttattgacatcatcaacgggcattacgccccgcctgccact
ajg904	tattgctcatcagcctcaacc
ajg905	gcctcacccaacgagtcctatg
ajg906	tggcggtcgaactggcgtcta
ajg907	gaagtgtctaagcaaccgcgcc
ajg908	gaagtgtctaagcaaccgcgccgatgacgcgcgaaaaagaaaaacggaggagcgcgcgatgacgacgcactttgcccgaat
ajg909	gaaccgacgagcagtaaaagccaatcaatggcagaataatggttaaggcaagcatgttcaattacgccccgcctgccact
ajg910	gaaccgacgagcagtaaaagcc
ajg911	aacgctgtcaccaacgcgcc
ajg930	ctcaaggcaccgtcgtcacca
ajg931	gaactcgagtaagtttttttc
ajg932	gaactcgagtaagttttttccgggttcttttaaaaatcagtcacaagtaaggtagggttcgacgcactttgcccgaat
ajg933	agtttatcgaaacaaaccatgatcttctcctaagcagtaaatggggccgcactctcgtggattacgccccgcctgccact
ajg934	agtttatcgaaacaaaccatg
ajg935	tgttgacgatctcgccagaga
ajg948	gcggcgtcatctatctctttt
ajg949	gcgttaattaaccaactggat
ajg950	gcgttaattaaccaactggatgatgtttgaggtgaaatgagtgaggaggcgaatgacgacgcactttgcccgaat
ajg951	gaaagcatcatttggagccggataaagcgcctacgcgtcgccatccggcgagaactcgtcttacgccccgcctgccact
ajg952	gaaagcatcatttggagccg
ajg953	agcgaagtcaaaggtgctga
ajg990	atacaatgcgcttaaatgcc
ajg991	aatcccgcctttattgtagaa
ajg992	aatcccgcctttattgtagaagcattggtacgcggcaactccgcaaggaacaggttgatttcgacgcactttgcccgaat
ajg993	gcactaccacctcaaggtagcgtgtctaccaattccaccacctcggcagggatactgctattacgccccgcctgccact
ajg994	gcactaccacctcaaggtagc
ajg995	gaaaaaaaaagacgcttttcag
ajg996	gaccattctgcccactgggctg
ajg997	gggatttgttctataatccc
ajg998	gggatttgttctataatcccgaatgacttgtattcagcaaagacatcgccactggattaagcgaacgcactttgcccgaat
ajg999	ttgcccgggttgcctcgcgggttggattgcaattgcctggtccttctaataaggaattacgccccgcctgccact
ajg1000	ttgcccgggttgcctcgcgg
ajg1001	gcattgtctgattccctgcc
ajg1050	aaaaatcctgattcgggtgag
ajg1051	gcttatcaggcctacaatcaa
ajg1052	gcttatcaggcctacaatcaaaaggcggctcatatgaccgccttttttattgcaacaaagcagcgcactttgcccgaat
ajg1053	cgcgtaaacagcgattaatgcgggttagtgaacgttcaactgacgaggggtgactaaaaacttacgccccgcctgccact

ajg1054	cgcgtaaacaggcagttaatg
ajg1055	tttaaagatggggacaattca
ajg1056	ctttggttttcacgcaacgca
ajg1057	ccactcaaaatgaagcctcgt
ajg1058	ccactcaaaatgaagcctcgtgcgcttcctaagtctattgtcgcggagttaagcagtacgacgcactttgcgccgaat
ajg1059	cccttcagcactttgttcagttgcatttctttaattccttttagtaaatcaattaattattattacgccccgccttgcact
ajg1060	cccttcagcactttgttcagt
ajg1061	cgcttcgctaccgtcattgc
ajg1062	ctttggttttcacgcaacgca
ajg1063	ccactcaaaatgaagcctcgt
ajg1064	ccactcaaaatgaagcctcgtgcgcttcctaagtctattgtcgcggagttaagcagtacgacgcactttgcgccgaat
ajg1065	gccaaccagtaacgacagactcaacaggtgatgtctgaagtactgctcatgaattctcttacgccccgccttgcact
ajg1066	gccaaccagtaacgacagact
ajg1067	tgagtgcgcggtccttcgacc
ajg1068	gaataagcgggttaactataa
ajg1069	atggcgctccacatatcgcaact
ajg1070	atggcgctccacatatcgcaactacaataagagctaacttaccagttcagggaaccacacgacgcactttgcgccgaat
ajg1071	tacaggtgcagggcattattcagatcttataatgagcgggcccgtcaggcccgttcacgtttttacgccccgccttgcact
ajg1072	tacaggtgcagggcattattc
ajg1073	ttgcaagcgttacgcgcttta
ajg1074	ttgcatgtgcgttggctgcac
ajg1075	tcctgaaacgtgacctattta
ajg1076	tcctgaaacgtgacctatttagagtattaaataagcagaaaagatgcttaagggatcacgcgacgcactttgcgccgaat
ajg1077	ctacggactcaggcaggtcgggaacaagaatatctacgctactcattattttacctttatttacgccccgccttgcact
ajg1078	ctacggactcaggcaggtcgg
ajg1079	agtttcgatttctaccagcac
ajg1080	ttgcatgtgcgttggctgcac
ajg1081	tcctgaaacgtgacctattta
ajg1082	tcctgaaacgtgacctatttagagtattaaataagcagaaaagatgcttaagggatcacgcgacgcactttgcgccgaat
ajg1083	taaaggtggccaaccatgtcgaaaacggacatttatctgttcccgaggaaacagcaggttttacgccccgccttgcact
ajg1084	taaaggtggccaaccatgtcg
ajg1085	ttacaaagccaataattttat

291

292 **Table S1.** Primer sequences used in this study.